Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.

Journal of the National Cancer Institute - 6 Dec 2006

Li Jing, Karlsson Mats O, Brahmer Julie, Spitz Avery, Zhao Ming, Hidalgo Manuel, Baker Sharyn D

Abstract excerpt

BACKGROUND: Gefitinib is an orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) with activity in non-small-cell lung cancer. The response to gefitinib is variable, possibly because of interindividual variation in the activity of cytochrome P450 3A (CYP3A), the principal enzyme that metabolizes gefitinib. We prospectively assessed the influence of CYP3A activity on gefitinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Environmental Exposure

Share to ErbB Receptors

Share to Gefitinib

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 17148773
DOI: 10.1093/jnci/djj466

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.PMID 17148773Read ↗

Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.Semantic proximity Read ↗

CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.Semantic proximity Read ↗

Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers.Semantic proximity Read ↗

A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe.Semantic proximity Read ↗

Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients.Semantic proximity Read ↗

Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping.Semantic proximity Read ↗

CYP3A activity: towards dose adaptation to the individual.Semantic proximity Read ↗

Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.Semantic proximity Read ↗

Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.Semantic proximity Read ↗

Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study.Semantic proximity Read ↗

Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.Semantic proximity Read ↗

Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.